

February 24, 2026,

To our valued customers,

I am pleased to introduce myself as the CEO of Precision IO Group Inc., the newly formed entity created through the combination of Quantum Surgical and NeuWave Medical.

As CEO, my main goals are to ensure we place customers at the center of everything we do, while advancing cutting-edge innovation into our portfolio to address your needs and improve patient outcomes.

You have already collaborated with at least one of the two companies. I would like to assure you that our products will continue to operate independently to ensure a smooth and uninterrupted experience for users:

- Quantum Surgical's Epione robotic solution remains an open architecture platform compatible with common forms of CT imaging and tumor ablation modalities, providing physicians with the flexibility to treat distinct tumor morphologies
- The NeuWave Medical microwave ablation platform is an established leader in interventional oncology and will continue to be used independently or combined with other therapies to improve outcomes for patients.

At the same time, Quantum Surgical and NeuWave are highly complementary and share a bold vision for the future. Having met both teams, I have been impressed by the pride and passion they bring to their work to enhance patient care.

I believe that the technologies, both independently and combined, have the potential to transform cancer care on a global scale.

Innovation is our North Star. Drawing on my 40 years of experience in minimally invasive surgery, I am convinced that AI, robotics, and enabling remote interventions are game changers for cancer care and interventional radiology and that, by partnering with you, we can democratize access to percutaneous ablation.

Together, we will shape the pillars of our technology and innovation roadmap for the future.

We are already advancing impactful initiatives designed to support and enhance your practice. For instance, our new remote project aims to expand access to robotic-assisted percutaneous procedures by leveraging world-renowned experts for remote trajectory planning and post-treatment assessment, using Epione tools.

The combined strength of our R&D teams — across AI, robotics, hardware & software, and navigation — will immediately accelerate innovation, enabling the introduction of new features in the short, mid, and long term.

Interventional oncology is entering an unprecedented era of innovation and possibility, raising the bar for patient outcomes. In this new chapter, we look forward to your continued input and feedback as we partner with you to achieve meaningful results that support and grow your practice.

For a start, Quantum Surgical and NeuWave look forward to connecting with you in person at SIR in Toronto, Canada, from April 11-15 and at ECIO in Basel, Switzerland, from April 26 to 30. In the meantime, please don't hesitate to reach out if you have any questions.

Thank you for your trust,

Sincerely,

A handwritten signature in black ink that reads 'Kurt Azarbarzin' in a cursive script.

Kurt Azarbarzin

CEO of Precision IO Group Inc.